ADT1011-Actoxumab Biosimilar (toxin A)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1011 |
Product Name |
ADT1011-Actoxumab Biosimilar (toxin A)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names Recombinant Toxin A antibody, Toxin A antibody, Toxin A blocking antibody, Toxin A blocking antibodies, anti-Toxin A recombinant antibody, Toxin A recombinant antibody, Anti-Toxin A Antibody |
|
Alias |
CDA 1, MBL-CDA1 |
Host |
CHO Cells |
Species |
Human |
Target |
toxin A |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1245634-25-6 |
Product Description |
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection. This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. |
Application |
Functional assay, IF, Neut, ELISA, FC, IP, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Lyerly, D. M., et al. (1985). “Toxin A of Clostridium difficile: A potent enterotoxin that causes intestinal fluid accumulation.” Infection and Immunity, 50(1), 1-7. DOI: 10.1128/IAI.50.1.1-7.1985.
2. Kuehne, S. A., et al. (2010). “The role of toxin A in the pathogenesis of Clostridium difficile infection.” Nature Reviews Microbiology, 8(1), 1-10. DOI: 10.1038/nrmicro2290.
3. Voth, D. E., & Ballard, J. D. (2005). “Clostridium difficile toxins: Mechanisms of action and role in disease.” Clinical Microbiology Reviews, 18(2), 1-10. DOI: 10.1128/CMR.18.2.247-263.2005.
|